A phase III, randomized, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GlaxoSmithKline Biologicals' measles-mumps-rubella vaccine (Priorix) and varicella vaccine (Varilrix)

Trial Profile

A phase III, randomized, controlled study to evaluate the immunogenicity and safety of three production lots of GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella (MeMuRu-OKA) candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GlaxoSmithKline Biologicals' measles-mumps-rubella vaccine (Priorix) and varicella vaccine (Varilrix)

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2007

At a glance

  • Drugs Measles mumps and rubella virus vaccine; MMR-varicella zoster virus vaccine; Varicella zoster virus vaccine
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top